8-K: LENZ Therapeutics Secures US FDA Approval for VIZZ Presbyopia Eye Drop

LENZ Therapeutics announced the US Food and Drug Administration (FDA) approved VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia in adults.

Summary

• The US FDA approved VIZZ (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in adults.
• VIZZ is the first and only FDA-approved aceclidine-based eye drop for presbyopia.
• It is the first once-daily solution proven to improve near vision for up to 10 hours.
• Samples are expected in the United States as early as October 2025, with commercial product broadly available by mid-Q4 2025.
• Direct-to-eye care professional sales and marketing activities will be initiated immediately.
• The approval was based on results from three randomized, double-masked, controlled Phase 3 studies (CLARITY 1, 2, and 3) involving 466 and 217 participants, respectively.
• In CLARITY 1 and 2, VIZZ improved near vision within 30 minutes and lasted up to 10 hours.
• Aceclidine, the sole active ingredient in VIZZ, is a new chemical entity in the United States.
• Presbyopia, the target condition, impacts approximately 128 million adults in the United States and an estimated 1.8 billion people globally.

Sentiment

Score: 9

Explanation: The FDA approval of a first-in-class, once-daily treatment for a large market like presbyopia is a highly significant positive event for a pharmaceutical company, indicating a clear path to commercialization and revenue generation. The positive clinical trial results and management's optimistic outlook further contribute to a very strong positive sentiment.

Positives

• FDA approval of VIZZ (aceclidine ophthalmic solution) 1.44% for presbyopia, marking a significant regulatory milestone for LENZ Therapeutics.
• VIZZ is the first and only FDA-approved aceclidine-based eye drop for presbyopia, offering a unique treatment option.
• It is the first once-daily solution with proven efficacy for up to 10 hours, providing extended relief for patients.
• Aceclidine, the sole active ingredient, is a new chemical entity in the United States, highlighting innovation.
• Clinical trials (CLARITY 1, 2, and 3) demonstrated rapid near vision improvement within 30 minutes.
• VIZZ was well-tolerated in trials, with no serious treatment-related adverse events observed over 30,000 treatment days.
• Its mechanism of action is predominantly pupil-selective miotic, interacting with the iris with minimal ciliary muscle stimulation, leading to a pinhole effect without causing a myopic shift.
• The product is preservative-free and provided in single-dose vials.

Negatives

• Common reported adverse reactions in clinical trials included instillation site irritation (20%), dim vision (16%), and headache (13%).
• Other adverse reactions reported in >5% of participants were conjunctival hyperemia (8%) and ocular hyperemia (7%).
• Temporary dim or dark vision may be experienced after using VIZZ, advising against driving or operating machinery if vision is not clear.

Risks

• Forward-looking statements are subject to substantial risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievement to be materially different from the information expressed or implied.
• Risks include those described in the 'Risk Factors' section of the company's Quarterly Report on Form 10-Q filed for the quarter ended June 30, 2025, and subsequent SEC filings.
• Cannot assure that the forward-looking statements or the assumptions upon which they are based will prove to be accurate.

Future Outlook

LENZ Therapeutics anticipates VIZZ samples to be available in the United States as early as October 2025, with broad commercial product availability by mid-Q4 2025. The company plans to initiate direct-to-eye care professional sales and marketing activities immediately and continues to establish international licensing partnerships to provide global access to VIZZ. Management believes VIZZ could immediately become the standard of care for presbyopia.

Management Comments

• "The FDA approval of VIZZ is a defining moment for LENZ and represents a transformative improvement in the available treatment options for the 128 million adults living with blurry near vision in the United States. We are ready and excited to launch the first and only once-daily eye drop with proven efficacy for up to 10 hours into the market." Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics.
• "This significant milestone is the result of tremendous commitment and collaboration by the LENZ team and our partners, the dedication of our clinical investigators, and the contributions of hundreds of participants in our clinical trials. I want to thank each of them for their role in getting VIZZ FDA approved." Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics.
• "This FDA approval represents a disruptive paradigm shift in treatment options for millions of people who are frustrated and struggling with the inevitable age-related loss of their near vision. I believe this will be a welcome solution for both optometrists and ophthalmologists who will now be able to offer a highly effective and sought-after presbyopia treatment that could immediately become the standard of care, with a product profile that will meet our patients needs." Marc Bloomenstein, OD, FAAO, VIZZ clinical investigator.

Industry Context

The approval of VIZZ introduces a new class of treatment for presbyopia, a widespread age-related vision condition affecting 128 million adults in the US. As the first and only FDA-approved aceclidine-based eye drop, and the first once-daily solution with 10-hour efficacy, VIZZ offers a differentiated mechanism of action (pupil-selective miotic with minimal ciliary muscle stimulation) compared to existing treatments like reading glasses, bifocals, or multifocal contact lenses, and potentially other pharmaceutical eye drops for presbyopia. This could disrupt the current market by providing a non-surgical, convenient, and effective pharmaceutical option.

Comparison to Industry Standards

• VIZZ is positioned as the "first and only aceclidine-based eye drop approved" for presbyopia, distinguishing it from other miotic agents or existing treatments.
• It is highlighted as the "first once daily solution to treat blurry near vision with proven efficacy for up to 10 hours," suggesting a superior duration of action compared to other daily drops, if any exist, or the convenience over multiple daily applications.
• The filing states it "could immediately become the standard of care," implying a significant improvement over current common treatments like reading glasses or other corrective aids, but does not name specific competing pharmaceutical products or companies for direct comparison.
• Its mechanism of action, a "predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation," is presented as unique, achieving a sub-2mm pupil without causing a myopic shift, which differentiates it from other miotics that might induce more ciliary muscle spasm or myopic shift.

Stakeholder Impact

• Shareholders: Significant positive impact due to FDA approval, potential for future revenue growth, and increased market value.
• Patients (Adults with Presbyopia): Access to a new, convenient, and effective once-daily eye drop treatment for blurry near vision, potentially improving quality of life.
• Eye Care Professionals (Optometrists and Ophthalmologists): New treatment option to offer patients, potentially becoming a standard of care.
• Employees: Positive impact on job security and potential for growth within the company due to product launch and commercialization.

Next Steps

• Initiate direct-to-eye care professional sales and marketing activities immediately.
• Make VIZZ samples available in the United States as early as October 2025.
• Achieve broad commercial product availability by mid-Q4 2025.
• Host a conference call and webcast on August 1, 2025, to discuss the approval.
• Continue to establish international licensing partnerships to provide global access to VIZZ.

Key Dates

Recommendation

The FDA approval of VIZZ is a transformative event for LENZ Therapeutics, validating its lead product and opening up a significant market opportunity (128 million US adults, 1.8 billion globally). As the first and only aceclidine-based, once-daily eye drop with proven 10-hour efficacy, VIZZ has a strong competitive profile and the potential to become a standard of care. This milestone significantly de-risks the investment and provides a clear path to commercialization and revenue generation, making it a compelling 'strong buy' for investors seeking growth in the pharmaceutical sector.

Keywords

FDA approval, presbyopia, VIZZ, aceclidine, eye drop, ophthalmic solution, near vision, LENZ Therapeutics, pharmaceutical, clinical trials